Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KSQ-001EX |
Synonyms | |
Therapy Description |
Limited information is currently available on KSQ-001EX, a putative therapy comprising tumor infiltrating lymphocytes with inactivation of SOCS1 (Feb 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KSQ-001EX | KSQ 001EX|KSQ001EX | Limited information is currently available on KSQ-001EX, a putative therapy comprising tumor infiltrating lymphocytes with inactivation of SOCS1 (Feb 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06237881 | Phase Ib/II | Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |